Abstract 3270
Background
Symptoms of anxiety and depression are common in patients with cancer, and associated with impaired quality of life (QoL). The aim was to evaluate the effect of internet-based stepped care (iCAN-DO) on symptoms of anxiety and depression and QoL in patients with cancer, compared to standard care (SC).
Methods
iCAN-DO was developed in cooperation between professionals and patients with cancer. Consecutive patients (N = 245), with self-reported symptoms of anxiety and/or depression, according to the Hospital Anxiety and Depression Scale, were randomized to iCAN-DO or SC. iCAN-DO comprised interactive support, including psycho-education and self-care strategies (Step 1), and cognitive behavioural therapy (Step 2) for those with persistent symptoms 1, 4 and/or 7 months post randomization. Data was collected before randomization and at 1, 4, 7 and 10 months post randomization.
Results
One-hundred and five of 124 patients (85%) used iCAN-DO to some extent and 49% completed the 10 months assessment. Patients randomized to iCAN-DO reported lower levels of symptoms of depression (mean 7.3 vs 6.2), and a clinically significant decrease of depression from baseline to 10 months (decrease 23% vs 8%), compared to standard care (p < 0.05). In addition, the proportion of patients with clinical depression was smaller in iCAN-DO (15% vs 23%) compared to SC, at 10 months (p < 0.05). There was now difference between iCAN-DO and SC with regard to symptoms of anxiety and QoL.
Conclusions
Internet-based stepped care for patients with cancer who self-report symptoms of anxiety and/or depression is effective to decrease depression, for some patients. Further studies are needed to develop internet-based support to suit different needs, and competence to use information technologies.
Clinical trial identification
NCT01630681.
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University Psychosocial Care Programme.
Funding
Swedish government, Forte Research Council, Swedish Cancer Society, Uppsala County Council.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1357 - Upfront atezolizumab chemoimmunotherapy-associated Immune-related adverse events in patients with advanced non-small cell lung cancer
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
1851 - Nivolumab-induced and radiation recall pneumonitis in patients with non-small cell lung cancer: a multicenter real world analysis of 669 patients
Presenter: Nobuaki Mamesaya
Session: Poster Display session 1
Resources:
Abstract
851 - Retrospective analysis of immunotherapy prognostic scores in advanced NSCLC at Nottingham University Hospitals (UK)
Presenter: Cristina Lopez Escola
Session: Poster Display session 1
Resources:
Abstract
3639 - Applicability of lung immune prognostic index (LIPI) to predict efficacy of first-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC)
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 1
Resources:
Abstract
2950 - Delayed Onset Immune Related Adverse Effects (IRAEs) of Pembrolizumab in Non-Small Cell Lung Cancer
Presenter: Haixi Yan
Session: Poster Display session 1
Resources:
Abstract
3659 - Clinical implication of multiplex IHC and serologic biomarkers on Hyperprogression in NSCLC patients receiving Immune checkpoint blockers in real world.
Presenter: Joori Kim
Session: Poster Display session 1
Resources:
Abstract
4882 - Local ablative treatment and treatment beyond progression for oligo-progression in stage IV non-small cell lung cancer after tumor response to anti-PD1 treatment
Presenter: Florian Guisier
Session: Poster Display session 1
Resources:
Abstract
1358 - Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
Presenter: Francis Mogollon-Duffo
Session: Poster Display session 1
Resources:
Abstract
2170 - Prognostic Impact of Metastatic Sites for Pembrolizumab Efficacy as First-line therapy in Patients with PD-L1 tumor proportion score (TPS) ≥ 50% Advanced Non–Small Cell Lung Cancer: A Retrospective Multicenter Study
Presenter: Hayato Kawachi
Session: Poster Display session 1
Resources:
Abstract
3051 - Impact of visceral fat area as independent predictive factor in patients with advanced non-small cell lung cancer treated with nivolumab
Presenter: Yuki Sato
Session: Poster Display session 1
Resources:
Abstract